References
- Svenska nationella kvalitetsregistret för lymfom [Internet]. [cited 2022 Sep 5]. Available from: https://statistik.incanet.se/Lymfom/.
- Harrysson S, Eloranta S, Ekberg S, et al. Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—a population‐based study of 736 patients. Br J Haematol. 2022;198(2):267–277. doi: 10.1111/bjh.18197.
- Regionala. Cancercentrum. Nationellt Vardprogram - aggressiva B-cellslymfom [Internet]. 2023 Jan [cited 2023 Mar 15]. Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/blod-lymfom-myelom/lymfom/vardprogram/nationellt-vardprogram-aggressiva-b-cellslymfom.pdf.
- Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large b-cell lymphoma. N Engl J Med. 2022;386(7):640–654. doi: 10.1056/NEJMoa2116133.
- Kite Pharma, A Gilead Company. ZUMA-7 trial data, CSR OS addendum [Data on File]. 2022.
- Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching [internet]. London: National Institute for Health and Care Excellence (NICE); 2014 [cited 2022 Apr 5]. (NICE Decision Support Unit Technical Support Documents). Available from: http://www.nicedsu.org.uk
- Neelapu SS, Jacobson CA, Ghobadi A, et al. 5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023;141(19):2307–2315. 2022018893. doi: 10.1182/blood.2022018893.
- Medicinrådet. [Danish Medicines Council.]. Baggrund for Medicinrådets anbefaling vedrørende axicabtagene ciloleucel som mulig standardbehandling til diffust storcellet B-cellelymfom [Internet]. 2019 May [cited 2023 Aug 21]. Available from: https://medicinraadet.dk/media/oxclkejt/baggrund-for-medicinraadets-anbefaling-vedr-axicabtagene-ciloleucel-til-diffust-storcellet-b-celle-lymfom-vers-1-0-mbilag_adlegacy.pdf.
- Norwegian Medicines Agency. Axicabtagene ciloleucel (Yescarta) for the treatment of second or later relapsed/refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) [Internet]. 2018 Jun. Available from: https://legemiddelverket.no/Documents/Offentlig%20finansiering%20og%20pris/Metodevurderinger/A/Axicabtagene%20ciloleucel%20(Yescarta)_ID2017_105%20-hurtig%20metodevurdering%20oppdatert.pdf.
- Tandvårds- och läkemedelsförmånsverket (TLV). [The Dental and Pharmaceutical Benefits Agency]. Underlag för beslut i landstingen, Yescarta (axicabtagene ciloleucel), Infusion av autolog chimär antigenreceptor T-cellsterapi Internet]. 2018 Nov. Available from: https://www.tlv.se/download/18.192533fa166f516fb27bb5ab/1542290744988/bes181107_underlag_yescarta.pdf.
- Fimea. Aksikabtageenisiloleuseeli (Yescarta) Aikuisten Suurisoluisten B-Solulymfoomien Hoidossa, Uusien sairaalalääkkeiden nopea arviointi [Internet]. 2018. Available from: https://www.fimea.fi/documents/160140/1454401/Fimea+KAI+16+2018+Aksikabtageenisiloleuseeli+(Yescarta)+aikuisten+suurisoluisten+B-solulymfoomien+hoidossa.pdf/9437de37-4d09-3b93-9c98-5981473a6b6b.
- Jacobson CA, Locke FL, Ghobadi A, et al. Long-Term (4- and 5-Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel in Patients with Refractory Large B-Cell Lymphoma. Available from: https://kitemedinfo.com/wp-content/uploads/2021/12/ASH2021_Jacobson_ZUMA-1-5-Yr-ASH_Poster-Layout_17Nov2021_FINAL_v2.pdf.
- Assouline S, Li S, Gisselbrecht C, et al. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. Blood Adv. 2020;4(9):2011–2017. doi: 10.1182/bloodadvances.2020001646.
- Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era: population-based outcomes in DLBCL. Cancer. 2017;123(17):3326–3334. Sep 1doi: 10.1002/cncr.30739.
- Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073. doi: 10.1200/JCO.2013.51.5866.
- Vadgama S, Mann J, Bashir Z, et al. Predicting survival for chimeric antigen receptor T-cell therapy: a validation of survival models using follow-up data from ZUMA-1. Value Health. 2022;25(6):1010–1017. doi: 10.1016/j.jval.2021.10.015.
- KOL validation interview Sweden 30 May. [transcript data on file]. 2022.
- Kite Pharma, A Gilead Company. A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma [Internet]. clinicaltrials.gov; 2023 Feb [cited 2023 Mar 16]. Report No.: NCT03391466. Available from: https://clinicaltrials.gov/ct2/show/NCT03391466.
- Kite Pharma, A Gilead Company. A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults with Refractory Aggressive Non-Hodgkin Lymphoma [Internet]. clinicaltrials.gov; 2022 Oct [cited 2023 Mar 16]. Report No.: NCT02348216. Available from: https://clinicaltrials.gov/ct2/show/NCT02348216.
- Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621–635. doi: 10.1023/a:1013171831202.
- Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997; 35(11):1095–1108. doi: 10.1097/00005650-199711000-00002.
- van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715. doi: 10.1016/j.jval.2012.02.008.
- Tandvårds-och läkemedelsförmånsverket (TLV). [The Dental and Pharmaceutical Benefits Agency]. Underlag för beslut i landstingen: libtayo (cemiplimab) [Internet]. Tandvårds- och läkemedelsförmånsverket; 2020. Available from: https://www.tlv.se/download/18.2baebd8016fa89b59b5176e2/1579177514292/bes_200113_underlag_libtayo.pdf.
- National Institute for Health and Care Excellence (NICE). Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [TA567] [Internet]. 2019 [cited 2022 Jun 10]. Available from: https://www.nice.org.uk/guidance/ta567/history.
- National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies [TA559] [Internet]. 2019 [cited 2022 May 12]. Available from: https://www.nice.org.uk/guidance/ta559/evidence/appraisal-consultation-committee-papers-pdf-6661404973.
- Kite pharma, A Gilead Company. Supplemental analysis of patient reported outcomes (PRO) data collected from kite pharma’s ZUMA-7 phase III trial (KTE-C19-107). [Data on File]. 2020.
- National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies Technology appraisal guidance [TA872] [Internet]. 2023 [cited 2023 May 30]. Available from: https://www.nice.org.uk/guidance/ta872.
- Kite Pharma, A Gilead Company. ZUMA-7 trial data [Data on File]. 2022.
- Tandvårds- och läkemedelsförmånsverket. (TLV) [The Dental and Pharmaceutical Benefits Agency]. Räkna AUP och AIP [Internet]. [cited 2023 Mar 16]. Available from: https://www.tlv.se/apotek/rakna-aup.html.
- European Medicines Agency. Breyanzi (lisocabtagene maraleucel) [Internet]. 2021 [cited 2023 Sep 6]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi.
- Region Östergötland. Prislista 2022 - Klinisk immunologi och transfusionsmedicin [Internet]. 2022. Available from: https://vardgivarwebb.regionostergotland.se/pages/88036/Prislista%20klinisk%20immunologi%20och%20transfusionsmedicin%202021-2022.xlsx.
- Södra Regionvårdsnämnden. REGIONALA PRISER OCH ERSÄTTNINGAR FÖR SÖDRA SJUKVÅRDSREGIONEN [Internet]. 2022. Available from: https://sodrasjukvardsregionen.se/download/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2022/?wpdmdl=24791&masterkey=61decc148fc78.
- European Medicines Agency. Minjuvi (tafasitamab) [Internet]. 2021 [cited 2023 Sep 6]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi.
- Region Stockholm. Prislista Avtalsläkemedel Region Stockholm och Region Gotland juni 2022 [file] [Internet]. Region. Stockholm. [cited 2022 Jun 1]. Available from: https://contracts.tendsign.com/ContractArea/Details/1579312?eId=2XwXmS0zykSquwLRsSricwA%3d.
- Tandvårds- och läkemedelsförmånsverket (TLV) [The Dental and Pharmaceutical Benefits Agency]. Underlag för beslut i landstingen Yescarta (axicabtagene ciloleucel) [Internet]. 2018 [cited 2023 Mar 16]. Available from: https://www.tlv.se/download/18.192533fa166f516fb27bb5ab/1542290744988/bes181107_underlag_yescarta.pdf.
- NT-rådet. Nationellt ordnat införande av nya läkemedel [Internet]. 2023 [cited 2023 Sep 6]. Available from: https://www.janusinfo.se/nationelltinforandeavlakemedel.4.7c82b0fc1638b8db71b12b21.html.
- Swedish Association of Local Authorities and Regions. Prognosis for LPI and LPIK. [Internet]. [cited 2023 Mar 21]. Available from: https://skr.se/download/18.7bf04e091864ab301c4775b/1676374358017/LPIKtabell-20230216.xlsx.
- Statistikmyndigheten. [Statistics Sweden. ]. Genomsnittlig timlön för arbetare inom privat sektor [Internet]. [cited 2022 Jun 27]. Available from: https://www.scb.se/hitta-statistik/statistik-efter-amne/arbetsmarknad/loner-och-arbetskostnader/konjunkturstatistik-loner-for-privat-sektor-klp/pong/tabell-och-diagram/arbetare/genomsnittlig-timlon-for-arbetare-inom-privat-sektor.
- Perales MA, Kuruvilla J, Snider JT, et al. The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial. Transplant Cell Ther. 2022;28(11):750.e1–750.e6.;S2666636722015482. doi: 10.1016/j.jtct.2022.08.010.
- Elsawy M, Chavez JC, Avivi I, et al. Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (Axi-Cel) versus standard of care therapy in patients with relapsed/refractory large B-Cell lymphoma (ZUMA-7). Blood. 2021;138(Supplement 1):430–430. doi: 10.1182/blood-2021-147598.
- Swedish Association of Local Authorities and Regions. LPI and LPIK 1980 - 2021 [Internet]. [cited 2023 Mar 21]. Available from: https://skr.se/download/18.fd18b1117fc1c31f5636714/1648730323474/2022-03-Tabellbilaga-LPI-LPIK-1980%E2%80%932021.xlsx.
- Skåne V. Region Skåne - Prislistor bild- och funktionsmedicin [Internet]. 2022 [cited 2022 Jun 27]. Available from: https://vardgivare.skane.se/patientadministration/avgifter-och-prislistor/prislistor-bild-funktionsmedicin/.
- European Medicines Agency. Columvi (glofitamab) [Internet]. 2023 [cited 2023 Sep 6]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/columvi.
- 1177 Region Skåne. Stamcellstransplantation [Internet]. 2021 cited 2022 Jun 27]. Available from: https://www.1177.se/Skane/behandling–hjalpmedel/operationer/transplantationer/stamcellstransplantation/#section-95356.
- Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5(20):4149–4155. Oct 26doi: 10.1182/bloodadvances.2020003848.
- Tandvårds-och läkemedelsförmånsverket (TLV). [The Dental and Pharmaceutical Benefits Agency]. Yervoy (ipilimumab) Hälsoekonomiskt kunskapsunderlag [Internet]. TLV; Available from: https://www.tlv.se/download/18.467926b615d084471ac33ac1/1510316361032/halsoekonomiskt-kunskapsunderlag-yervoy_forsta_linjen.pdf.
- Kunskapsbanken. Knowledge support for those who work in cancer care - RCC Kunskapsbanken [Internet]. [cited 2022 Jun 27]. Available from: https://kunskapsbanken.cancercentrum.se/.
- Ishak KJ, Proskorovsky I, Korytowsky B, et al. Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics. 2014;32(6):533–546. doi: 10.1007/s40273-014-0145-y.
- van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544–551. doi: 10.1200/JCO.2016.69.0198.
- National Institute for Health and Care Excellence (NICE). Single Technology Appraisal Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy [ID1684] Committee Papers [Internet]. 2023 [cited 2023 May 15]. Available from: https://www.nice.org.uk/guidance/gid-ta10580/documents/committee-papers-2.
- Statistikmyndigheten. [Statistics Sweden]. Population aged 15-74 (Labor Force Survey), percent by sex, age, labour status and year [Internet]. 2022. [cited 2023 Aug 20]. Available from: https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__AM__AM0401__AM0401A/NAKUBefolkning2Ar/table/tableViewLayout1/.
- Tandvårds-och läkemedelsförmånsverket (TLV). [The Dental and Pharmaceutical Benefits Agency]. Tandvårds- och läkemedelsförmånsverkets allmänna råd [Internet]. 2017 [cited 2022 Jun 10]. Available from: https://www.tlv.se/download/18.467926b615d084471ac3230c/1510316374332/TLVAR_2017_1.pdf.
- European Medicines Agency. Kymriah (tisagenlecleucel) [Internet]. 2021 cited 2023 Sep 6]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah.